tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

TOVX Stock Latest News

Theriva Biologics to discuss trial design for VIRAGE
The FlyTheriva Biologics to discuss trial design for VIRAGE
6d ago
TOVX
Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
PremiumPress Releases
Theriva™ Biologics to Discuss the Trial Design for VIRAGE – a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma – at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
6d ago
TOVX
Theriva Biologics’ VCN-01 Shows Promise in Pediatric Cancer Trial
PremiumCompany Announcements
Theriva Biologics’ VCN-01 Shows Promise in Pediatric Cancer Trial
8d ago
8K
TOVX
Theriva Biologics announces topline data from Phase 1 trial of VCN-01
PremiumThe Fly
Theriva Biologics announces topline data from Phase 1 trial of VCN-01
8d ago
TOVX
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
PremiumCompany Announcements
Theriva Biologics Reports Breakthrough in Pancreatic Cancer Therapy
9d ago
8K
TOVX
Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
PremiumPress ReleasesTheriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting
9d ago
TOVX
Theriva Biologics Upcoming Investor Presentations Insight
PremiumCompany Announcements
Theriva Biologics Upcoming Investor Presentations Insight
15d ago
8K
TOVX
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
PremiumPress Releases
Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results
1M ago
TOVX
Theriva Biologics expects cash to provide runway into 1Q25
PremiumThe Fly
Theriva Biologics expects cash to provide runway into 1Q25
1M ago
TOVX
Theriva Biologics reports 2023 EPS ($1.14) vs. ($1.31) last year
PremiumThe Fly
Theriva Biologics reports 2023 EPS ($1.14) vs. ($1.31) last year
1M ago
TOVX
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
PremiumPress Releases
Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results
1M ago
TOVX
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
PremiumPress Releases
Theriva™ Biologics to Participate in the BIO-Europe Spring Conference
2M ago
TOVX
Theriva Biologics VIRAGE Trial Progresses Positively
PremiumCompany AnnouncementsTheriva Biologics VIRAGE Trial Progresses Positively
3M ago
8K
TOVX
Theriva Biologics Reports Positive Phase 2b Trial Progress
PremiumCompany Announcements
Theriva Biologics Reports Positive Phase 2b Trial Progress
3M ago
8K
TOVX
Theriva says IDMC recommends continuation of enrollment as planned in VIRAGE
PremiumThe Fly
Theriva says IDMC recommends continuation of enrollment as planned in VIRAGE
3M ago
TOVX
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
PremiumPress Releases
Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results
6M ago
TOVX
Theriva Biologics reports Q3 EPS (19c), consensus (37c)
PremiumThe Fly
Theriva Biologics reports Q3 EPS (19c), consensus (37c)
6M ago
TOVX
Theriva™ Biologics to Participate in the BIO-Europe Conference
PremiumPress Releases
Theriva™ Biologics to Participate in the BIO-Europe Conference
6M ago
TOVX
Theriva Biologics, SJD advance strategic collaboration
PremiumThe Fly
Theriva Biologics, SJD advance strategic collaboration
6M ago
TOVX
Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
PremiumPress ReleasesTheriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023
6M ago
TOVX
Theriva Biologics presents data from Phase 1 trial of VCN-01
PremiumThe Fly
Theriva Biologics presents data from Phase 1 trial of VCN-01
6M ago
TOVX
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
PremiumPress Releases
Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
7M ago
TOVX

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >